Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCORE: Sintilimab Induction Plus Concurrent Chemoradiotherapy for High-Risk Locally Advanced Cervical Cancer
ChiCTR2500109302Phase 2Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of sintilimab in Cervical Cancer (CC) (2 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: 2-year progression-free survival rate. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2500109302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109302.